408
K. Namekata et al.: Cytokine Changes in Hepatectomy Patients
SIRS(ϩ) group than in the SIRS(Ϫ) group (Fig. 1).
Therefore, SIRS(ϩ) cases can be predicted by measur-
ing the serum IL-6, h-HGF, and 7S levels on POD 1,
and may thus allow for the early determination of
cases likely to develop postoperative complications and
MODS. In addition, considering the fact that progres-
sion to SIRS(ϩ) is frequent in cases of liver dysfunction
before operation (Table 3), SIRS(ϩ) cases can be pre-
dicted by measuring the preoperative serum levels of
PT, HPT, ChE, and ICG-R15.
The frequency of postoperative complications is con-
sidered to depend on the duration of SIRS, rather than
the number of SIRS-related signs.24 In this study, all 4
patients in whom the SIRS(ϩ) lasted for 3 days or
longer developed postoperative complications. Renal
dysfunction (serum creatinine level м1.0mg/dl) is also
considered to be associated with an increased incidence
of SIRS and postoperative complications, since the
cytokine clearance is reduced.24 In this study, in 5 out of
8 SIRS(ϩ) patients with postoperative complications
the serum creatinine level was elevated to 1.0mg/dl or
higher, thus suggesting that the decrease in cytokine
clearance is related to SIRS. In one patient the SIRS(ϩ)
lasted for 2 days, and was complicated by renal dysfunc-
tion (serum creatinine level of 1.67mg/dl) and sepsis
induced by intraperitoneal methicillin-resistant Staphy-
lococcus aureus infection. A second elevation of the
serum levels of IL-6, h-HGF, and 7S was observed on
POD 3 and the liver dysfunction persisted, thus result-
ing in MODS. The outcome in this case suggested that
the decrease in cytokine clearance was also related to
the severity of SIRS.
serum levels of IL-6, h-HGF, and 7S were regarded to
be SIRS(ϩ). In such patients, intensive management
directed against postoperative complications, septic
SIRS, and MODS is therefore required.
References
1. American College of Chest Physicians/Society of Critical Care
Medicine Consensus (1992) Definitions for sepsis and organ fail-
ure and guidelines for the use of innovative therapies in sepsis.
Crit Care Med 20:864–874
2. Davies MG, Hagen PO (1997) Systemic inflammatory response
syndrome. Br J Surg 84:920–935
3. Lemaire LC, van Lanschot JJ, Stoutenbeek CP, van Deventer SJ,
Wells CL, Gouma DJ (1997) Bacterial translocation in multiple
organ failure: cause or epiphenomenon still unproven. Br J Surg
84:1340–1350
4. Andus TI, Bauer JO, Gerok WO (1991) Effects of cytokines on
the liver. Hepatology 13:364–375
5. Maruyama H, Harada A, Kurokawa T, Nonami T, Nakao A,
Takagi H (1994) Interleukin-6 as a marker of hepatic metabolism
following hepatectomy. Hepatogastroenterology 41:222–224
6. Tomiya T, Tani M, Yamada S, Hayashi S, Umeda N, Fujiwara K
(1992) Serum hepatocyte growth factor levels in hepatectomized
and nonhepatectomized surgical patients. Gastroenterology 103:
1621–1624
7. Shimahara Y, Yamamoto N, Kobayashi N (1997) postoperative
care in patients with liver damage (in Japanese). Shokaki Geka
(Gastroenterol Surg) 20:475–479
8. Kimura F, Miyazaki M, Suwa T, Kakizaki S, Itoh H, Kaiho T,
Ambiru S, Shimizu H, Togawa A (1996) Increased levels of
human hepatocyte growth factor in serum and peritoneal fluid
after partial hepatectomy. Am J Gastroenterol 91:116–121
9. Ogawa M (1995) The significance of the concepts of systemic
inflammatory response syndrome (SIRS) in gastroenterological
surgery (in Japanese). Shokaki Geka (Gastroenterol Surg)
18:149–157
10. Ohzato H, Yoshizaki K, Nishimoto N, Ogata A, Tagoh H,
Monden M, Gotoh M, Kishimoto T, Mori T (1992) Interleukin-6
as a new indicator of inflammatory status: detection of seum levels
of interleukin-6 and C-reactive protein after surgery. Surgery
111:201–209
11. Shimada M, Matsumata T, Takemoto A, Shirabe K, Yamamoto
K, Takenaka K, Sugimachi K (1995) The role of interleukin-6,
interleukin-1â, tumor necrosis factor-α and endotoxin in hepatic
resection. Hepatogastroenterology 42:691–697
12. Aleksander K (1989) The role of interleukin-6 as the hepatocyte
stimulating factor in the network of inflammatory cytokines. In:
Sehgal PB, Grieninger G, Tosato G (eds) Regulation of the acute
phase and immune response: interleukin 6. Ann NY Acad Sci
557:1–8
Utilizing SIRS as one of the warning signs for
determining serious cases is thus considered to be effec-
tive9,15,25 since it may require strict and intensive man-
agement in order to avoid progression to MODS. After
a hepatectomy, the serum peak levels of IL-6, h-HGF,
and 7S were significantly higher in the SIRS(ϩ) cases
(Fig. 2), and were thus found to be a useful marker for
predicting postoperative SIRS(ϩ).
In 8 SIRS(ϩ) patients with postoperative complica-
tions and 4 patients with SIRS(ϩ) lasting for 3 days or
longer, no significant elevation was found in the pre-
operative serum IL-6 and h-HGF levels. However, the
preoperative serum 7S levels in these cases were
significantly higher than in other cases (P Ͻ 0.05) (Table
4).
In summary, we demonstrated that the measurements
of serum IL-6, h-HGF, and 7S levels before and im-
mediately after surgery may be important indices for
predicting the occurrence of SIRS and postoperative
complications after a hepatectomy. Especially, patients
with liver dysfunction before the operation with an el-
evated serum 7S level of about 7ng/ml or higher before
the operation, and with higher postoperative maximum
13. Heinrich PC, Castell JV, Andus TI (1990) Interleukin-6 and the
acute phase response. Biochem J 265:621–636
14. Damas PI, Ledoux DI, Nys MO, Vrindts YV, Groote DO,
Franchimont PA, Lamy MA (1992) Cytokine serum level during
severe sepsis in human IL-6 as a marker of severity. Ann Surg
215:356–362
15. Ono S, Tamakuma S, Mochizuki H, Kinoshita M, Aosasa S (1995)
Postoperative complication and SIRS (in Japanese). Shokaki
Geka (Gastroenterol Surg) 18:201–207
16. Maeba T, Maeta H, Usuki H, Wakabayashi H, Tsubouchi T,
Okada E, Takeda T, Hamamoto I, Okano K, Ishimura K (1996)
Increase in portal blood interleukin-6 soon after the commence-
ment of digestive surgery. Surg Today 26:890–894
17. Michalopoulos GK, Zanger R (1992) Hepatocyte growth factor.
Hepatology 15:149–155